secwatch.observer — SEC 8-K summary
======================================

Issuer:     IO Biotech, Inc. (IOBTQ)
CIK:        0001865494
Form:       8-K
Filed at:   2022-10-13T23:59:59+00:00
Accession:  0001193125-22-262152
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

IO Biotech appoints Amy Sullivan as CFO effective Oct 15, 2022
--------------------------------------------------------------

- Amy Sullivan, 53, appointed CFO and Principal Financial Officer, effective October 15, 2022.
- Annual base salary of $425,000 and target bonus of 45% of base salary.
- Granted option for 288,152 shares; vests 25% at 1 year, then monthly over 3 years.
- Ms. Sullivan previously served as CFO at TABA and chief strategy officer at Kiadis Pharma, leading its sale to Sanofi.
- She brings 25+ years of life sciences finance and corporate strategy experience.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1865494/000119312522262152/0001193125-22-262152-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1865494/000119312522262152/d412480d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-262152

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer